Trending
CJC-1295 and Ipamorelin Research: Identity, Testing and Supply
2026-11-01 · 3 min read
CJC-1295 and Ipamorelin attract research interest because they engage different receptor pathways associated with growth hormone signaling. For laboratories, however, recognizing the names is only a starting point. Exact molecular identity, the distinction between DAC-containing and non-DAC materials, and lot-specific analytical documentation all affect whether a product is suitable for a defined experiment. This overview focuses on those research and procurement questions—not personal use or treatment.
What Researchers Study About CJC-1295 and Ipamorelin
CJC-1295 is a modified analog of growth hormone-releasing hormone, or GHRH. Ipamorelin is a peptide agonist at the growth hormone secretagogue receptor, commonly called the ghrelin receptor. Their different receptor targets provide a basis for investigating distinct inputs into growth hormone signaling, but they do not make the compounds interchangeable.
Research involving either compound must be interpreted in the context of the experimental model, material tested, analytical methods, and measured endpoints. Results from receptor assays, animal studies, and human investigations answer different questions. Findings from one setting should not be presented as proof of clinical benefit or as instructions for using research-grade material.
CJC-1295 Identity: Why the DAC Distinction Matters
The name CJC-1295 can be used inconsistently in supplier catalogs. The compound described in the original CJC-1295 development literature includes a drug affinity complex, or DAC, modification designed to facilitate albumin binding. Products marketed as “CJC-1295 without DAC” often refer to a modified GRF(1–29) peptide rather than the same molecular entity with equivalent properties.
Before ordering, request the stated sequence, molecular formula, expected molecular mass, and description of any linker or conjugation chemistry. A catalog name alone is not sufficient to establish identity. Researchers should match the supplied material to the compound specified in their protocol rather than assume all CJC-labeled products are equivalent.
The same principle applies to products that combine CJC-labeled material with Ipamorelin. A blend should identify both components and their stated amounts or ratio. Separate-compound findings do not automatically establish the behavior, stability, or analytical suitability of a combined formulation.
Testing Beyond a Headline Purity Percentage
A useful certificate of analysis connects the vial lot to identifiable test results. HPLC can characterize chromatographic purity under the stated method, while mass spectrometry can support molecular identity by comparing observed and expected mass. Neither result, by itself, establishes every aspect of product quality.
An HPLC area percentage is not automatically a measurement of peptide content per vial. It also does not establish sterility, endotoxin status, or absence of every possible contaminant. Laboratories should determine which additional measurements their application requires and check whether those tests were actually performed.
For blends, ask whether the analytical method can distinguish the components and whether their amounts were independently measured. A single overall purity figure may not resolve component identity or proportion. Lot numbers, test dates, laboratory identification, and method information make a COA more useful for procurement review.
Wholesale Kit Buying and Laboratory Receiving
Wholesale American Peptides supplies research peptides in 10-vial kits with a one-kit minimum and a third-party COA per lot. For CJC-1295 or Ipamorelin procurement, confirm current availability, exact molecular identity, vial specifications, and whether the offering contains separate compounds or a blend before purchasing.
Volume discounts are 5% at two kits, 7% at three kits, 12% at five kits, and 20% at ten kits. Shipping costs $19.99 for one to two kits and $24.99 for three to four kits, with free shipping for five or more kits. Compare purchasing quantities against projected experimental needs, storage capacity, and the value of maintaining lot consistency.
On receipt, reconcile labels and lot numbers with the COA, document package condition, and follow the product-specific storage instructions. A lyophilized presentation alone does not establish room-temperature stability or a universal shelf life. All materials are for research use only and are not for human or veterinary administration.
Frequently asked
- Are CJC-1295 and Ipamorelin the same type of research peptide?
- No. CJC-1295 is a GHRH analog, while Ipamorelin acts at the growth hormone secretagogue receptor. They engage different receptor pathways, so experimental selection should follow the research question and protocol.
- Is CJC-1295 without DAC equivalent to CJC-1295 with DAC?
- No. Products labeled without DAC often refer to modified GRF(1–29), whereas DAC-containing CJC-1295 includes additional chemistry associated with albumin binding. Verify the sequence, modifications, and expected mass rather than relying on the product name.
- Does high HPLC purity confirm the amount of peptide in each vial?
- Not by itself. HPLC area purity describes the relative chromatographic signal under a particular method. Confirming peptide content per vial requires an appropriate quantitative measurement; purity and content are different specifications.
- What is the minimum order at Wholesale American Peptides?
- The minimum is one 10-vial kit. Each lot has a third-party COA. Confirm current compound availability and specifications before ordering; all products are for research use only.